<p>Indian vaccine manufacturer Bharat Biotech has received regulatory approval to carry out a phase-3 clinical trial of its Covid-19 vaccine, which came out in flying colours in phase-I/II of the trial.</p>.<p>The phase-3 trial is likely to be conducted on more than one thousand individuals to find if the vaccine offers any lasting protection.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/national/india-has-set-aside-7-billion-to-vaccinate-world-s-second-biggest-population-905653.html" target="_blank">India has set aside $7 billion to vaccinate world’s second-biggest population </a></strong></p>.<p>Named Covaxin, the vaccine is made from an ineffective strain of the Covid-19 virus isolated at the National Institute of Virology, Pune.</p>.<p>The Drugs Controller General of India had approved the phase-3 trial on October 20 based on the results of the phase-I/II trial and animal studies.</p>.<p>The regulator asked the company to be extra careful in picking up the right candidates as the recipient of the vaccine.</p>.<p>Numerous such vaccines, including the shots for seasonal influenza, Polio, Pertussis, Rabies and Japanese Encephalitis, use the same technology.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/election-2020/opposition-slams-bjps-free-covid-19-vaccine-pitch-for-bihar-polls-905569.html" target="_blank">Opposition slams BJP's 'free Covid-19 vaccine' pitch for Bihar polls </a></strong></p>.<p>Once the vaccine is injected into a human, it has no potential to infect or replicate, since it is a killed virus. It just serves the immune system as a dead virus to mount an antibody response towards the virus.</p>.<p><strong>New treatment option</strong></p>.<p>Meanwhile, Pune-based Serum Institute of India has joined hands with the International AIDS vaccine Initiative and pharmaceutical giant Merck to produce a type of monoclonal antibodies against Covid-19 for the world.</p>.<p>An effective and safe method of treatment, monoclonal antibodies offer an alternate therapeutic regimen for Covid-19 as several of them are various stages of research and development.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/world-news-politics/ailments-in-covid-19-trials-raise-questions-about-vaccine-method-903365.html" target="_blank">Ailments in Covid-19 trials raise questions about vaccine method</a></strong></p>.<p>SII and Merck would develop SARS-CoV-2 neutralising monoclonal antibodies co-invented by IAVI and Scripps Research as an innovative intervention to address the pandemic.</p>.<p>Neutralising antibodies are widely considered to be promising candidates for Covid-19 treatment and prevention.</p>.<p>Encouraging results for Covid-19 antibody treatment have emerged from preclinical research and initial clinical trials.</p>
<p>Indian vaccine manufacturer Bharat Biotech has received regulatory approval to carry out a phase-3 clinical trial of its Covid-19 vaccine, which came out in flying colours in phase-I/II of the trial.</p>.<p>The phase-3 trial is likely to be conducted on more than one thousand individuals to find if the vaccine offers any lasting protection.</p>.<p><strong>Read | <a href="https://www.deccanherald.com/national/india-has-set-aside-7-billion-to-vaccinate-world-s-second-biggest-population-905653.html" target="_blank">India has set aside $7 billion to vaccinate world’s second-biggest population </a></strong></p>.<p>Named Covaxin, the vaccine is made from an ineffective strain of the Covid-19 virus isolated at the National Institute of Virology, Pune.</p>.<p>The Drugs Controller General of India had approved the phase-3 trial on October 20 based on the results of the phase-I/II trial and animal studies.</p>.<p>The regulator asked the company to be extra careful in picking up the right candidates as the recipient of the vaccine.</p>.<p>Numerous such vaccines, including the shots for seasonal influenza, Polio, Pertussis, Rabies and Japanese Encephalitis, use the same technology.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/election-2020/opposition-slams-bjps-free-covid-19-vaccine-pitch-for-bihar-polls-905569.html" target="_blank">Opposition slams BJP's 'free Covid-19 vaccine' pitch for Bihar polls </a></strong></p>.<p>Once the vaccine is injected into a human, it has no potential to infect or replicate, since it is a killed virus. It just serves the immune system as a dead virus to mount an antibody response towards the virus.</p>.<p><strong>New treatment option</strong></p>.<p>Meanwhile, Pune-based Serum Institute of India has joined hands with the International AIDS vaccine Initiative and pharmaceutical giant Merck to produce a type of monoclonal antibodies against Covid-19 for the world.</p>.<p>An effective and safe method of treatment, monoclonal antibodies offer an alternate therapeutic regimen for Covid-19 as several of them are various stages of research and development.</p>.<p><strong>Also Read | <a href="https://www.deccanherald.com/international/world-news-politics/ailments-in-covid-19-trials-raise-questions-about-vaccine-method-903365.html" target="_blank">Ailments in Covid-19 trials raise questions about vaccine method</a></strong></p>.<p>SII and Merck would develop SARS-CoV-2 neutralising monoclonal antibodies co-invented by IAVI and Scripps Research as an innovative intervention to address the pandemic.</p>.<p>Neutralising antibodies are widely considered to be promising candidates for Covid-19 treatment and prevention.</p>.<p>Encouraging results for Covid-19 antibody treatment have emerged from preclinical research and initial clinical trials.</p>
